Article

Chronic lymphocytic leukaemia: an update

memo - Magazine of European Medical Oncology 04/2012; 2(3):142-145. DOI:10.1007/s12254-009-0144-4 pp.142-145

ABSTRACT Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in Europe and North America, and mainly affects older individuals.
It has a very variable course, with survival ranging from months to decades. Major progress has been made in the identification
of molecular and cellular markers that may predict prognosis in CLL patients. However, these advances have raised new questions
about the biology, prognosis and management of CLL. Available treatments generally induce remission, although nearly all patients
relapse and CLL remains an incurable disease. Advances in molecular biology have enhanced our understanding of the pathophysiology
of the disease and, together with the development of new therapeutic agents, have made CLL management more rational and more
effective. This review describes the recent advances concerning the prediction of prognosis involving novel molecular genetic
techniques and treatment of CLL patients suggesting an evidence-based approach according to individual risk factors.

0 0
 · 
0 Bookmarks
 · 
30 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

cellular markers
 
Chronic lymphocytic leukaemia
 
CLL
 
CLL management
 
CLL patients
 
common leukaemia
 
decades
 
Europe
 
evidence-based approach
 
incurable disease
 
individual risk factors
 
Major progress
 
molecular biology
 
new questions
 
new therapeutic agents
 
North America
 
older individuals
 
variable course